Full Title
Phase 1/2 Study of HLD-0915 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)Purpose
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
In this study, researchers want to find the best dose of HLD-0915 to use in people with CRPC. HLD-0915 is part of a class of drugs called small-molecule inhibitors. These drugs are small enough to enter cells easily.
Once inside the cells, they can affect other molecules, such as proteins, and may cause cancer cells to die. HLD-0915 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have CRPC that keeps growing even though you had anti-cancer drugs for advanced prostate cancer.
- Have recovered from the serious side effects of previous therapies before taking HLD-0915.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Charles Ryan’s office at 646-422-4371.